New answers to age-old questions, such as adjusting the dose to account for drug interactions, reducing side effects, maintaining weight, and protecting that finicky organ—the kidneys.
This study won’t tell us if “sluggish cognitive tempo” is a valid disorder, but it does show how Vyvanse works in this controversial subtype of ADHD. Research Update
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
